Business Context and Reporting Period
This Form 6-K filing is submitted by Midatech Pharma PLC (noted as Biodexa Pharmaceuticals Plc in metadata) for the month of November 2018. The registrant is a foreign private issuer headquartered in Abingdon, Oxfordshire, United Kingdom, filing under Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to incorporate a press release by reference and contains no financial statements or quantitative performance data.
Material Changes
No material changes to financial performance or operations are reported in this document. The filing focuses exclusively on a corporate governance matter regarding stock listing compliance.
Guidance, Outlook, and Material Events
- Material Event: The filing incorporates Exhibit 99.1, a press release dated November 1, 2018, titled "NASDAQ Minimum Bid Price Extension."
- Context: The company is addressing compliance with NASDAQ listing requirements, specifically regarding the minimum bid price.
- Management Commentary: No specific outlook or guidance is provided in the text of this filing.
Investor Verification Checklist
- Verify the specific terms and duration of the NASDAQ Minimum Bid Price Extension granted to the company.
- Confirm the current stock price relative to the NASDAQ minimum bid requirement.
- Review the full text of the press release (Exhibit 99.1) for details on the company's plan to regain compliance.
- Note the discrepancy between the metadata company name (Biodexa) and the filing registrant name (Midatech Pharma PLC).